Mitchell P. Rales
Mitchell P. Rales's purchase track record
Mitchell P. Rales has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/16/2022 | ESAB | $20.00M | +32.1% | +34.0% | +5.1% |
| 5/16/2022 | DHR | $50K | +22.9% | +8.5% | -1.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Danaher Expands AI Integration in Scientific Research. Danaher has announced a partnership to integrate AI into scientific research workflows, a move that could enhance its diagnostic and drug discovery capabilities. With Q3 earnings approaching, investors are watching to see if this strategic shift supports the company's recovery narrative. The stock currently trades near its 52-week high, reflecting optimism about these operational improvements.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Enovis joins AAOS Registry Program as industry sponsor. Enovis has become the first multi-registry industry sponsor of the AAOS Registry Program. This move highlights the company's engagement with major orthopedic data initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $38.33.
Transaction History
| ESAB | ▲ Buy | Grant | 892 | $0 | 9/30/2026 | View on chart |
| DHR | ▲ Buy | Grant | 500,000 | $0 | 8/4/2026 | View on chart |
| ESAB | ▲ Buy | Grant | 596 | $0 | 6/30/2026 | View on chart |
| ESAB | ▼ Sell | Gift | 111,346 | $0 | 6/1/2026 | View on chart |
| ESAB | ▼ Sell | Other | 70,686 | $0 | 6/1/2026 | View on chart |
| ESAB | ▼ Sell | Other | 3,355,765 | $0 | 6/1/2026 | View on chart |
| ESAB | ▲ Buy | Grant | 813 | $0 | 5/8/2026 | View on chart |
| ESAB | ▲ Buy | Grant | 570 | $0 | 3/31/2026 | View on chart |
| DHR | ▼ Sell | Gift | 71,648 | $0 | 2/27/2026 | View on chart |
| ESAB | ▲ Buy | Grant | 493 | $0 | 12/31/2025 | View on chart |
| DHR | ▼ Sell | Open Market | 35,899 | $8.3M | 11/25/2025 | View on chart |
| DHR | ▼ Sell | Open Market | 4,726 | $1.1M | 11/25/2025 | View on chart |
| DHR | ▼ Sell | Gift | 22,029 | $0 | 11/25/2025 | View on chart |
| DHR | ▼ Sell | Open Market | 25,855 | $5.6M | 11/12/2025 | View on chart |
| DHR | ▼ Sell | Open Market | 254,553 | $55.6M | 11/12/2025 | View on chart |
| DHR | ▼ Sell | Open Market | 133,233 | $29.2M | 11/12/2025 | View on chart |
| DHR | ▼ Sell | Open Market | 23,359 | $5.1M | 11/12/2025 | View on chart |
| DHR | ▼ Sell | Open Market | 223,449 | $48.3M | 10/31/2025 | View on chart |
| DHR | ▼ Sell | Open Market | 308,423 | $66.5M | 10/31/2025 | View on chart |
| DHR | ▼ Sell | Open Market | 68,128 | $14.8M | 10/31/2025 | View on chart |
| ESAB | ▲ Buy | Grant | 493 | $0 | 9/30/2025 | View on chart |
| ESAB | ▲ Buy | Grant | 457 | $0 | 6/30/2025 | View on chart |
| ESAB | ▲ Buy | Grant | 637 | $0 | 5/8/2025 | View on chart |
| ESAB | ▲ Buy | Grant | 473 | $0 | 3/31/2025 | View on chart |
| DHR | ▼ Sell | Gift | 616 | $0 | 11/21/2024 | View on chart |
| ESAB | ▲ Buy | Grant | 3,567 | $0 | 8/5/2024 | View on chart |
| DHR | ▼ Sell | Other | 50,175 | $10.0M | 4/17/2023 | View on chart |
| ESAB | ▲ Buy | Open Market | 500,000 | $20.0M | 11/16/2022 | View on chart |
| DHR | ▲ Buy | Open Market | 100 | $25K | 5/16/2022 | View on chart |
| DHR | ▲ Buy | Open Market | 100 | $25K | 5/16/2022 | View on chart |
| ENOV | ▼ Sell | Other | 1,600,000 | — | 1/15/2022 | View on chart |
| DHR | ▼ Sell | Open Market | 104,174 | $31.7M | 11/4/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 70,463 | $21.5M | 11/4/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 54,269 | $16.6M | 11/4/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 54,115 | $16.6M | 11/4/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 30,089 | $9.3M | 11/4/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 29,587 | $9.1M | 11/4/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 1,165 | $361K | 11/4/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 194,257 | $59.4M | 11/4/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 38,225 | $11.6M | 11/3/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 69,024 | $21.1M | 11/3/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 52,888 | $16.3M | 11/3/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 40,138 | $12.3M | 11/3/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 47,168 | $14.5M | 11/3/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 78,923 | $24.4M | 11/3/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 16,002 | $5.0M | 11/3/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 1,493 | $465K | 11/3/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 56,106 | $17.6M | 11/2/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 10,269 | $3.2M | 11/2/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 79,925 | $25.0M | 11/2/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 194,542 | $60.9M | 11/2/2021 | View on chart |
| DHR | ▼ Sell | Open Market | 3,019 | $950K | 11/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
ESAB Schedules Q3 2026 Earnings Call Amid Mixed Stock Performance
ESAB has announced the schedule for its third-quarter 2026 earnings release and conference call. This announcement follows a period of mixed price action, with recent reports noting both sharp declines and significant gains in the stock. The company is preparing to share updated financial results as investors monitor its performance against a 52-week range of $64.83 to $137.42.
ESAB Schedules Q3 2026 Earnings Call Amid Mixed Stock Performance. ESAB has announced the schedule for its third-quarter 2026 earnings release and conference call. This announcement follows a period of mixed price action, with recent reports noting both sharp declines and significant gains in the stock. The company is preparing to share updated financial results as investors monitor its performance against a 52-week range of $64.83 to $137.42.